Evidence map›Paper›PMID 39805387›Full record

ReviewCancer letters2025

Interrogation of the tumor microenvironment by nanoparticles.

Prasanta Panja, Upender Manne, Vibhudutta Awasthi, Resham Bhattacharya, Priyabrata Mukherjee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Prasanta PanjaDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Upender ManneDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Vibhudutta AwasthiDepartment of Pharmaceutical Sciences, University of Oklahoma Health Science Center, Suite 309, 1110 N. Stonewall Avenue, Oklahoma City, OK, 73117, USA.
Resham BhattacharyaDepartment of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Priyabrata MukherjeeDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Electronic address: Priyabrata-Mukherjee@ouhsc.edu.

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery systemR01CA253391 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2021 to 2025
$1.7M
Reprogramming Tumor Microenvironment by NanoparticleR01CA213278 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2017 to 2021
$1.7M
Exploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA213278NCI NIH HHS R01 CA253391NCI NIH HHS R01 CA260449
6 · The paper itself

Abstract

The tumor microenvironment (TME) plays a pivotal role in cancer progression by fostering intricate multicellular crosstalk among cancer cells, stromal cells, and immune cells. This review explores the emerging paradigm of utilizing nanoparticles to disrupt this crosstalk within the TME as a therapeutic strategy. Nanoparticles are engineered with precise physicochemical properties to target specific cell types and deliver therapeutic payloads, thereby inhibiting critical signaling pathways involved in tumor growth, invasion, and metastasis. The mechanisms involved include modulation of the immune response, interference with growth factor signaling, and induction of programmed cell death in cancer cells. Challenges such as biocompatibility, efficient delivery, and potential development of resistance are discussed alongside promising advancements in nanoparticle design. Moving forward, integration of nanoparticle-based therapies with existing treatment modalities holds great potential for enhancing therapeutic efficacy and personalized medicine in cancer therapy.

Indexed as

NanoparticlesNeoplasmsTumor MicroenvironmentAnimalsHumansSignal TransductionCancer therapyMulticellular crosstalkNanomedicineTargetingTumor microenvironment

Identifiers

PMID39805387
PMCPMC13037733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.